Lilly To Invest $1.5 Bn in New Mfg Facilities
Eli Lilly and Company plans to invest over $1 billion for a new manufacturing site for parenteral drugs (injectables) and devices in Concord, North Carolina, and $500 million for a new biopharmaceutical manufacturing facility in Limerick, Ireland.
Over the last five years, Lilly has invested over $4 billion in global manufacturing, including more than $2 billion in the US. The new $1-billion site in Concord, North Carolina, follows a $470- million investment, announced in 2020, in North Carolina’s Research Triangle Park. The new site in Concord will create nearly 600 new jobs for scientists, engineers, and manufacturing personnel, In addition, an estimated 500 additional positions will be required while the facility is under construction.
The investment in Concord is contingent upon completion of county and municipal government permitting and related approvals.
Lilly also plans to invest $500 million in a new biopharmaceutical (active ingredient) manufacturing facility in Limerick, Ireland. The project is subject to planning approval, and the company will submit a planning application with Limerick City and County Council in the coming weeks (as reported on January 28, 2022). The proposed project is expected to create more than 300 new jobs for workers such as engineers, scientists, and operations personnel and an estimated 500 additional positions while the facility is under construction.
Lilly says it anticipates additional future investments in manufacturing to address growth expected from potential new medicines to treat diabetes, Alzheimer’s disease, cancer and autoimmune conditions.